Headquartered in Waltham, MA Fiscal year ends December NASDAQ: OPRX optimizerx.com
OptimizeRx Corp. (Nasdaq: OPRX) is a healthcare technology company that helps pharmaceutical and life sciences manufacturers reach and engage healthcare professionals (HCPs) and patients.
Its core asset is a point-of-care network integrated into more than 450 electronic health record (EHR) and e-prescribing systems, reaching over 1.1 million verified healthcare professionals. Through this network, brands deliver messaging within clinical workflows.
The company's AI-enabled products include:
- Dynamic Audience Activation Platform (DAAP), a patent-protected tool that identifies patients approaching treatment eligibility.
- Natural Language Audience Builder (NLAB), now extended to privacy-safe direct-to-consumer audiences.
- Micro-Neighborhood Targeting (MNT) for hyper-local DTC engagement.
- CopayCue, a recently introduced solution.
In 2026 the company opened its EHR network to programmatic buying through DeepIntent, The Trade Desk and PulsePoint. The goal is to move beyond direct sales toward a scalable, multi-channel distribution model.
Revenue is concentrated among large pharmaceutical manufacturers: the top 20 pharma companies account for 53% of trailing-12-month revenue. The company is expanding into mid-tier and long-tail life sciences, biotech and med-tech clients. Updated
The beat on both lines got buried: OptimizeRx cut full-year revenue guidance to $87 million to $93 million from $95 million to $100 million. Margins are the bright spot, with adjusted EBITDA margin near 29% versus about 20% a year ago.
OptimizeRx Corp. (Nasdaq: OPRX) is a healthcare technology company that helps pharmaceutical and life sciences manufacturers reach and engage healthcare professionals (HCPs) and patients.
The Wall Street consensus 12-month price target for OPRX is $12.60.